You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Advanced kidney cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kidney Cancer Trial in Tampa, Atlanta, Nashville (Blood Sparing Protocol, Standard Blood Replacement)

Suspended
  • Kidney Cancer
  • Blood Sparing Protocol
  • Standard Blood Replacement
  • Tampa, Florida
  • +2 more
Aug 26, 2022

Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

Completed
Has Results
  • Kidney Cancer
  • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Advanced Kidney Cancer Trial in Tianjin (Pembrolizumab plus Lenvatinib)

Recruiting
  • Advanced Kidney Cancer
  • Pembrolizumab plus Lenvatinib
  • Tianjin, Tianjin, China
    Changyi Quan
Aug 4, 2022

Advanced Kidney Cancer Trial in Tianjin (Tislelizumab Lenvatinib)

Recruiting
  • Advanced Kidney Cancer
  • Tislelizumab Lenvatinib
  • Tianjin, Tianjin, China
    Changyi Quan
Aug 4, 2022

Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma Trial in United States (Guadecitabine, Durvalumab)

Active, not recruiting
  • Advanced Kidney Cancer
  • +2 more
  • Chicago, Illinois
  • +4 more
Feb 16, 2022

Combined Postoperative Radiotherapy With Kidney Sparing Surgery

Recruiting
  • Locally Advanced
  • Urothelial Carcinoma Ureter
  • Radical surgery
  • Kidney sparing surgery+Postoperative radiotheray
  • Beijing, China
  • +1 more
Nov 2, 2023

Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations Trial (Axitinib 5 MG)

Available
  • Clear Cell Kidney Cancer
  • +2 more
  • Axitinib 5 MG
  • (no location specified)
Jul 3, 2023

Kidney Cancer Trial in Houston (Axitinib)

Active, not recruiting
Has Results
  • Kidney Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 2, 2022

Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma Trial in United States (Talazoparib, Axitinib)

Recruiting
  • Kidney Cancer
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 8, 2022

Renal Cancer Trial in New York (Magnetic Resonance Imaging (MRI) Scan, Tc-99m Pentetate)

Recruiting
  • Renal Cancer
  • Magnetic Resonance Imaging (MRI) Scan
  • Tc-99m Pentetate
  • New York, New York
    NYU Langone Health
Oct 31, 2023

Sarcoma, Carcinoma, Digestive Cancer Trial in Linyi (Recombinant oncolytic herpes simplex virus type 1 (R130))

Recruiting
  • Sarcoma
  • +9 more
  • Recombinant oncolytic herpes simplex virus type 1 (R130)
  • Linyi, Shandong, China
    Linyi Central Hospital
Jul 25, 2023

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Duarte (Clostridium

Active, not recruiting
  • Advanced Renal Cell Carcinoma
  • +5 more
  • Clostridium butyricum CBM 588 Probiotic Strain
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Oct 12, 2022

Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7 Trial in Houston (other,

Completed
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 30, 2022

Solid Tumor, Adult, Advanced Solid Tumor, Head Neck Cancer Trial in Irving, San Antonio, West Valley City (SNS-101 (anti-VISTA),

Recruiting
  • Solid Tumor, Adult
  • +19 more
  • Irving, Texas
  • +2 more
May 24, 2023

Kidney Cancer Trial in Cambridge (Magnetic Resonance Imaging)

Recruiting
  • Kidney Cancer
  • Magnetic Resonance Imaging
  • Cambridge, Cambridgeshire, United Kingdom
    University Department of Radiology
Aug 23, 2023

Cancer, Solid Tumor, Melanoma Trial (KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose

Not yet recruiting
  • Cancer
  • +16 more
  • KVA12123 - Dose Escalation
  • +3 more
  • (no location specified)
Feb 2, 2023

Describe Kidney Cancer Patient Population Treatment, and Results

Not yet recruiting
  • Renal Cell Cancer
  • +6 more
    • (no location specified)
    May 2, 2022

    Relapse, Advanced Malignant Tumor, Non Small Cell Lung Cancer Trial in India (AUR106)

    Not yet recruiting
    • Relapse
    • +7 more
    • Visakhapatnam, Andhra Pradesh, India
    • +5 more
    May 7, 2023

    Renal Cell Carcinoma, Kidney Tumor, Renal Cancer Trial in New York (Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250))

    Completed
    Has Results
    • Renal Cell Carcinoma
    • +3 more
    • Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    Cancer, Solid Tumor, Colorectal Cancer Trial (biological, radiation, drug)

    Not yet recruiting
    • Cancer
    • +8 more
    • DK210 (EGFR)
    • +3 more
    • (no location specified)
    Jan 27, 2023

    oncRNA Stratification of Cancer by Size and Stage

    Not yet recruiting
    • Kidney Cancer
    • +32 more
    • Exai oncRNA blood test
    • (no location specified)
    Apr 27, 2023

    Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,

    Recruiting
    • Advanced Clear Cell Renal Cell Carcinoma
    • +3 more
    • Aldesleukin
    • Pembrolizumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 5, 2022

    Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial

    Recruiting
    • Advanced Clear Cell Renal Cell Carcinoma
    • +3 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Dec 2, 2022

    Assess Safety and Effectiveness of Zirabev in Domestic Various

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +7 more
    • (no location specified)
    Jun 30, 2022